Wall Street achieved record highs as healthcare stocks saw notable movements.

Global stock markets surged this week on trade optimism, rate cut bets, and corporate updates.

Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss ...

Hims & Hers (HIMS) Rallies 11.76% as CEO Not Backing Down After Novo Nordisk Spat Published on June 27, 2025 at 2:22 pm by Angelica Ballesteros in News ...

People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently approved only for type 2 diabetes, according to results from a small trial.

Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk has bounced back from a sour ending to its Hims & Hers partnership, revealing a new deal with WeightWatchers to expand access to its blockbuster weight loss drug Wegovy (semaglutide). The ...

Wegovy (semaglutide) will no longer be available through Hims & Hers Health, as Novo Nordisk has ended its short-lived partnership.

Marketing GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride Month By Andrea Park Jun 26, 2025 3:31pm LGBTQ+ Diversity Novo Nordisk Novartis ...

Novo Nordisk is partnering with WeightWatchers to offer consumers access to Wegovy after it abruptly ended its collaboration with Hims & Hers.

(Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1. Under the deal, cash-paying patients can access a ...